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ResveratrolHyperglycemia-mediated oxidative stress plays a crucial role in the progression of diabetic nephropathy.
Hence, the present study was hypothesized to explore the renoprotective nature of resveratrol by assessing
markers of oxidative stress, proinﬂammatory cytokines and antioxidant competence in streptozotocin–
nicotinamide-induced diabetic rats. Oral administration of resveratrol to diabetic rats showed a signiﬁcant
normalization on the levels of creatinine clearance, plasma adiponectin, C-peptide and renal superoxide
anion, hydroxyl radical, nitric oxide, TNF-α, IL-1β, IL-6 and NF-κB p65 subunit and activities of renal aspartate
transaminase, alanine transaminase and alkaline phosphatase in comparison with diabetic rats. The altered
activities of renal aldose reductase, sorbitol dehydrogenase and glyoxalase-I and elevated level of serum
advanced glycation end products in diabetic rats were also reverted back to near normalcy. Further,
resveratrol treatment revealed a signiﬁcant improvement in superoxide dismutase, catalase, glutathione
peroxidase, glutathione-S-transferase and glutathione reductase activities and vitamins C and E, and reduced
glutathione levels, with a signiﬁcant decline in lipid peroxides, hydroperoxides and protein carbonyls levels in
diabetic kidneys. Similarly, mRNA and protein analyses substantiated that resveratrol treatment notably
normalizes the renal expression of Nrf2/Keap1and its downstream regulatory proteins in the diabetic group of
rats. Histological and ultrastructural observations also evidenced that resveratrol effectively protects the
kidneys from hyperglycemia-mediated oxidative damage. These ﬁndings demonstrated the renoprotective
nature of resveratrol by attenuating markers of oxidative stress in renal tissues of diabetic rats.ts; ALP, alkaline phosphatase;
Ccr, creatinine clearance; DTT,
; γ-GCS, γ-glutamylcysteine
one reductase; GSH, reduced
e oxygenase-1; Keap1, Kelch-
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Diabetes mellitus is a heterogeneous metabolic disorder essen-
tially characterized by insufﬁciency of insulin secretion and insulin
receptor or postreceptor events with derangement in carbohydrate,
protein and lipid metabolism resulting in chronic hyperglycemia.
Hyperglycemia is a well distinguished pathogenetic factor of long-
term complications in diabetes mellitus not only engenders excessive
free radicals but also attenuates antioxidative machineries through
glycation of the antioxidant enzymes. Hence, oxidative stress has been
considered to be a general pathogenic factor of diabetic complications
including nephropathy [1]. Diabetic nephropathy, an imperative
complication of diabetes mellitus, is characterized by the protuber-ance of the glomerular mesangium due to amassing of extracellular
matrix proteins synthesized by the mesangial cells with basement
membrane thickening, glomerular and tubular hypertrophy, glomer-
ulosclerosis and tubulointerstitial ﬁbrosis [2]. As hyperglycemia-
mediated oxidative stress plays a central role in the development and
progression of diabetic nephropathy, glycemic control remains the
focal target in the treatment of diabetic nephropathy.
Agents with signiﬁcant antioxidant potentials have been reported
to elicit protection on diabetic kidney damage. The antioxidants such
as taurine, melatonin, vitamin C and vitamin E are reported to reduce
the renal complications like glomerular hypertrophy, albuminuria,
glomerular collagen and renal protein kinase C activity in experi-
mental diabetes [3,4]. Glyclazide, the second generation sulfonylurea,
has also been shown to possess a notable antioxidant potential due to
its azabicyclo-octyl ring independent of glycemic control by scaveng-
ing free radicals, reducing the expression of NAD(P)H oxidase,
enhancing renal expression of Mn-superoxide dismutase and endo-
thelial nitric oxide synthase, suppressing glomerular macrophage
migration, thereby ameliorating glomerular matrix expansion and
albuminuria [5]. Hence, it is recommended that therapy with
antioxidants may signify a useful pharmacologic overture to the
management of diabetes. Therefore, the present study was aimed to
assess the antioxidant defensive as well as renal tissue protective
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nicotinamide-induced diabetic rats.
Resveratrol is a polyphenolic phytoalexin that occurs naturally in
many plant species, including grapevines and berries, and exhibits
surfeit of pharmacologic health beneﬁts including antioxidant [6],
antimutagenic [7], anti-inﬂammatory [8], estrogenic [9], antiplatelet
[10], anticancer [11] and cardioprotective properties [12]. There has
been copious epidemiologic and clinical evidence conﬁrming that
resveratrol may act as an antioxidant through enhancing hydrogen
peroxide tolerance and inhibiting cyclooxygenase-2 activity. Recently,
resveratrol has been reported to possess antihyperglycemic effect in
experimental diabetes [13], which is mediated by modulating the
activities of key carbohydrate metabolizing enzymes in the hepatic
and renal tissues of experimental diabetic rats [14,15]. More recently,
we have reported the pancreatic β-cell [16] as well as hepatocyte
protective nature of resveratrol from oxidative damage in streptozo-
tocin–nicotinamide-induced diabetic rats [17]. Moreover, very limited
studies have demonstrated the effect of resveratrol on diabetic kidney
by assessing the changes in phosphorylation of histone H3, levels of
the oxidative markers such as malondialdehyde and glutathione and
antioxidant enzymes such as superoxide dismutase and catalase in the
renal tissues of diabetic rats [18,19] and none of them have explored
the protective nature of resveratrol on renal tissue ultrastructure
during hyperglycemia- as well as proinﬂammatory cytokine-mediat-
ed oxidative damage in streptozotocin–nicotinamide-induced diabet-
ic rats. Hence, the present study was aimed to investigate the
ameliorative potential of resveratrol on proinﬂammatory cytokines,
hyperglycemia-mediated oxidative stress and renal dysfunction in
streptozotocin–nicotinamide-induced diabetic rats and the efﬁcacy of
resveratrol was compared with glyclazide, an oral antihyperglycemic
drug with antioxidant potential.
2. Materials and methods
2.1. Chemicals
Resveratrol, streptozotocin, nicotinamide, epinephrine, thiobarbi-
turic acid, reduced glutathione (GSH), vitamin E and sodium azide
were procured from Sigma Chemicals Co. (St. Louis, MO), stored at 2–
4 °C and protected from sunlight. All other chemicals were of
analytical grade and were obtained from standard commercial
suppliers.
2.2. Experimental animals
Animal experiments were premeditated and executed in accor-
dance with the ethical norms approved by Ministry of Social Justices
and Empowerment, Government of India and Institutional Animal
Ethics Committee Guidelines (Approval No.01/036/07). Six-week-old,
male, Wistar rats weighing 160–180 g, procured from Tamilnadu
Veterinary and Animal Sciences University, Chennai, India, were
housed in clean, sterile, polypropylene cages under standard vivarium
conditions (12 h light/dark cycle) with ad libitum access to water and
standard rat chow (Hindustan Lever Ltd., Bangalore, India) with a
composition of 5% fat, 21% protein, 55% nitrogen-free extract and 4%
ﬁber (w/w) with adequate mineral and vitamin levels for the animals.
The animals were acclimatized to the laboratory conditions for
2 weeks prior to the inception of experiments.
2.3. Induction of experimental diabetes
Experimental diabetes was induced in 12 h fasted rats by single i.p.
injection of streptozotocin (50 mg/kg body weight) dissolved in
100 mM cold citrate buffer, pH 4.5 [20], 15 min after the intraperi-
toneal administration of nicotinamide (110 mg/kg body weight) [21].
Since streptozotocin is capable of inducing fatal hypoglycemia as aresult of massive pancreatic insulin release, the rats were supplied
with 10% glucose solution after 6 h of streptozotocin administration
for the next 24 h to prevent hypoglycemia [22]. After a week in time
for the development and aggravation of diabetes, rats with moderate
diabetes (i.e. blood glucose concentration≥14 mM) were selected for
the experiment.2.4. Experimental design
The experimental animals were divided into ﬁve groups, each
group comprising of a minimum of six rats detailed as follows. Group
1 served as control rats; group 2 served as control rats daily
administered with resveratrol (5 mg/kg body weight) in aqueous
suspension orally for 30 days; group 3 served as streptozotocin–
nicotinamide-induced diabetic rats; group 4 served as diabetic rats
daily administered with resveratrol (5 mg/kg body weight) in
aqueous suspension orally for 30 days; and group 5 served as diabetic
rats daily administered with glyclazide (5 mg/kg body weight) in
aqueous suspension orally for 30 days.
During the experimental period, body weight, blood glucose, food
and water consumption and physical examinations were determined
at regular intervals. The dosage was adjusted every week according to
any change in body weight to maintain similar dose per kg body
weight of rat over the entire period of study for each group. At the end
of the treatment period, the rats were fasted overnight, anaesthetized
with ketamine (80 mg/kg body weight; i.p.) and killed by cervical
decapitation. The blood was collected with or without anticoagulant
for plasma or serum separation, respectively. Fasting blood glucose,
HbA1c and plasma insulin levels were determined to conﬁrm the
antihyperglycemic property of resveratrol [14,15].2.5. Preparation of kidney tissue homogenate
Kidney tissues from control and experimental groups of rats were
excised, rinsedwith ice-cold saline and homogenized in 100 mMTris–
HCl buffer (pH 7.4) using Teﬂon homogenizer and centrifuged at
12,000g for 30 min at 4 °C. The supernatant was pooled and used for
the estimations. The protein content in the tissue homogenate was
also estimated [23].2.6. Determination of intraperitoneal insulin tolerance
At the end of the experimental period, fasting blood samples were
withdrawn from the control and experimental groups of rats. Four
more blood samples were collected at 30, 60, 90 and 120 min intervals
after the intraperitoneal administration of a bolus of insulin (2 units/
kg body weight). All the blood samples were collected with
ethylenediaminetetraacetic acid (EDTA) for the determination of
glucose by using glucose oxidase peroxidase diagnostic enzyme kit
(Span Diagnostic Chemicals, Surat, India).2.7. Assessment of renal dysfunction
The levels of plasma and urinary creatinine (Pcr and Ucr) were
determined by alkaline picrate method using creatinine assay kit (Span
Diagnostics Ltd., Surat, India). Urine samples (24 h)were collectedusing
metabolic cages. Creatinine clearance (Ccr) was computed using the
following formula: Ccr (μl/min)=(Ucr/Pcr)×urine volume (μl/min).
The activities of pathophysiological enzymes such as aspartate
transaminase (AST), alanine transaminase (ALT) and alkaline phospha-
tase (ALP)were also assayed in the kidney tissue homogenate of control
and experimental groups of rats [24,25].
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The concentration of plasma adiponectin was determined by ELISA
(Biosource, Camarillo, CA) and plasma C-peptide assay was performed
byusinganELISAkit suppliedby LincoResearch Inc., St Charles,MO. Both
the analyses were done according to the manufacturer's instructions.
2.9. Assay of renal polyol pathway enzymes
The activities of aldose reductase [26], sorbitol dehydrogenase [27]
and glyoxalase-I [28] were determined in the kidney tissue homog-
enate of control and experimental groups of rats. The concentration of
serum advanced glycation end products (AGEs) was measured by
ELISA (Abcam, Cambridge, UK) as per the manufacturer's instructions.
2.10. Assay of TNF-α, IL-1β, IL-6 and NF-κB p65 subunit
The levels of proinﬂammatory cytokines such as TNF-α, IL-1β and
IL-6 in kidney tissues of control and experimental groups of rats were
determined by speciﬁc ELISA kits according to the manufacturer's
instructions (Biosource, Camarillo, CA). The concentration of proin-
ﬂammatory cytokines was determined spectrophotometrically at
450 nm. Standard plots were constructed by using standard cytokines
and the concentrations for unknown samples were calculated from
the standard plot. The nuclear level of p65 may correlate positively
with the activation of NF-κB pathway. The NF-κB/p65 ActivELISA
(Imgenex, San Diego, CA) kit was used to quantify NF-κB free p65 in
the nuclear fraction of kidney tissue homogenate. The analysis was
done according to the manufacturer's instructions.
2.11. Assay of renal superoxide radical, hydroxyl radical and total nitric
oxide (NO)
The generation of superoxide radical in the kidney tissue
homogenate of control and experimental groups of rats wasmeasured
spectrophotometrically at 510 nm using the cytochrome c method
and the superoxide radicals generated were expressed as absorbance
at 550 nm/15 min [29]. The generation of hydroxyl radical in the
kidney tissue of control and experimental groups of rats was
measured spectrophotometrically at 510 nm and was expressed as
absorbance at 510 nm/30 min [30]. The renal NO level was indirectly
measured by determining the nitrite level using a colorimetric
method based on the Griess reaction [31].
2.12. Measurement of hyperglycemia-mediated oxidative stress
The levels of non-enzymatic antioxidants such as vitamin C [32],
vitamin E [33] and GSH [34] were estimated in the kidney tissue
homogenate of control and experimental groups of rats. Further, the
levels of lipid peroxides [35], hydroperoxides [36] and protein
carbonyls [37] were determined in the kidney tissue homogenate of
control and experimental groups of rats. The activities of enzymatic
antioxidants such as superoxide dismutase (SOD) [38], catalase [39],
glutathione peroxidase (GPx) [40], glutathione-S-transferase (GST)
[41] and glutathione reductase (GR) [42] were assayed in the kidney
tissue homogenate of control and experimental group of rats.
2.13. Real-time qPCR analysis for Nrf2, Keap1, γ-Gcsh, and Gstm3
Total RNA was extracted from the renal tissues from control and
experimental groups of rats by TRIzol® reagent (Invitrogen, Carlsbad,
CA), according to the manufacturer's protocol and puriﬁed by Qiagen
RNeasy Mini Kit (Qiagen, Venlo, The Netherlands). Puriﬁed total RNA
was reverse transcribed into single strand cDNAs, which were
successively analyzed by real-time qPCR using the SYBR GREEN PCR
master mix (Applied Biosystems, Foster City, CA). The ampliﬁcationprotocol comprised of 1 cycle at 95 °C for 3 min followed by 40 cycles
at 95 °C for 30 s, 58 °C for 30 s, and then 72 °C for 30 s. Primer
sequences were designed using the Primer Express 2.0 software
ensuing the instructions of Applied Biosystems for optimal primer
design and were synthesized commercially. The primer sequences for
nuclear factor (erythroid-derived 2)-like 2 (Nrf2), Kelch-like ECH-
associated protein 1 (Keap1), γ-glutamylcysteine synthetase heavy
(catalytic) subunit (γ-Gcsh), Gstm3 and Gapdhwere given in Table 1. A
standard curve was prepared using a serial dilution of a reference
sample, and was included in each real-time run to correct for possible
variations in product ampliﬁcation. Relative copy numbers were
obtained from standard curve values, and were normalized to values
obtained for the internal control, Gapdh. The fold change in expression
was then obtained by 2−ΔΔCT method.
2.14. Western blot analysis for Nrf2, Keap1, γ-GCS, μ-GST and HO-1
The kidney tissues of control and experimental groups of rats were
homogenized in 1 ml of ice-cold hypotonic buffer A containing 10 mM
HEPES (pH 7.8), 10 mM KCl, 2 mM MgCl2, 1 mM dithiothreitol (DTT),
0.1 mM EDTA and 0.1 mM phenylmethylsulfonyl-ﬂuoride (PMSF). To
the tissue homogenate, 80 μl of 10% Nonidet P-40 solution was added
and the mixture was then centrifuged for 2 min at 14,000g. The
supernatant was collected as a cytosolic fraction. The precipitated
nuclei were washed once with 500 μl of buffer A plus 40 μl of 10%
Nonidet P-40, centrifuged, resuspended in 200 μl of buffer C contain-
ing 50 mM HEPES (pH 7.8), 50 mM KCl, 300 mM NaCl, 0.1 mM EDTA,
1 mM DTT, 0.1 mM PMSF, 20% glycerol and centrifuged for 5 min at
14,800g. The supernatant containing nuclear proteins was collected as
a nuclear fraction for Nrf2 analysis. Protein concentration was
determined by the method of Lowry et al. [23]. Protein (10 μg) was
loaded into each well and subjected to immunoblot analysis for Nrf2,
Keap1, γ-GCS, μ-GST and heme oxygenase (HO)-1 (Santa Cruz
Biotechnology Inc., Santa Cruz, CA). Band intensities were quantiﬁed
by densitometric analysis and the results were normalized to the
GAPDH expression in each group as percent of control.
2.16. Histological observations of kidney
A slice of kidney tissue was ﬁxed in 10% formalin for 1 week at
room temperature. Then the specimens were dehydrated in a graded
series of ethanol, cleared in xylene and embedded in parafﬁn wax.
Tissue blocks were sectioned into 5 μm thickness using a rotary
microtome. Sections were stained by hematoxylin–eosin. Histological
changes in the stained sections were viewed under the light
microscope by a pathologist without prior knowledge of the groups.
2.17. Transmission electron microscopic study
A portion of kidney (about 1 mm3) from control and experimental
groups of rats were ﬁxed in 3% glutaraldehyde in 200 mM sodium
phosphate buffer (pH 7.4) for 3 h at 4 °C. Tissue samples were washed
with the same buffer and post-ﬁxed in 1% osmium tetroxide and
200 mM sodiumphosphate buffer (pH 7.4) for 1 h at 4 °C. The samples
were again washed with the same buffer for 3 h at 4 °C, dehydrated
with graded series of ethanol and embedded in Araldite. Thin sections
were cut with LKBUM4 ultramicrotome using a diamond knife
(Diatome, Aldermaston, Berkshire, England), mounted on a copper
grid and stained with 2% uranyl acetate and Reynolds lead citrate. The
grids were examined under a Philips EM201C transmission electron
microscope (Philips, Eindhoven, Netherlands).
2.18. Statistical analysis
The results were expressed as mean±SEM of six rats per group
and statistical signiﬁcance was evaluated by one-way ANOVA using
Table 1
List of primer sequences for real-time qPCR.
Accession no. Gene description Gene symbol Forward Reverse Product size
NM_031789.1 Nuclear factor (erythroid-derived 2)-like 2 Nrf2 gagacggccatgactgat gtgaggggatcgatgagtaa 196
NM_057152.1 Kelch-like ECH-associated protein 1 Keap1 ctgcatccaccacagcagcgt gtgcagcacacagaccccggc 250
NM_012815.2 γ-Glutamylcysteine synthetase heavy subunit γ-Gcsh atgcagtattctgaactacc acaaactcagattcacctac 396
NM_020540.1 Glutathione-S-transferase, mu 3 Gstm3 gaacgttcgcggacttactca acgtatctcttctcctcatagtttg 78
NM_017008.3 Glyceraldehyde-3-phosphate dehydrogenase Gapdh aggttgtctcctgtgacttc ctgttgctgtagccatattc 130
Fig. 1. Effect of resveratrol on the intraperitoneal insulin tolerance test in control and
experimental groups of rats. Values are expressed as mean±SEM for groups of six rats
in each. Statistical signiﬁcance was determined by one-way ANOVA followed by post
hoc test LSD. Asterisk (*) indicating a pb0.05 versus control rats; double asterisk (**)
indicating a pb0.05 versus diabetic rats.
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signiﬁcant difference (LSD). Values were considered statistically
signiﬁcant when pb0.05.
3. Results
3.1. Resveratrol improves insulin tolerance after insulin challenge in
diabetic rats
The effect of resveratrol as well as glyclazide treatment on the level
of blood glucose in the control and experimental groups of rats
receiving an intraperitoneal insulin challenge is shown in Fig. 1. The
blood glucose level is signiﬁcantly (pb0.05) reduced in diabetic rats
treated with resveratrol as well as glyclazide than that of diabetic
group of rats. However, slight reduction of blood glucose is observed
in diabetic group of rats in comparison with control group of rats.
Conversely, there is no signiﬁcant reduction in the blood glucose of
control rats treated with resveratrol when compared with control
group of rats. This assay indicated improved insulin sensitivity in
resveratrol treated diabetic rats and is comparable with glyclazide
treated diabetic group of rats.
3.2. Resveratrol normalizes renal dysfunction in diabetic rats
Table 2 epitomizes the effect of resveratrol on the body weight,
relative organweight of kidney, creatinine clearance and the activities of
renal AST, ALT and ALP in the control and experimental groups of rats.
There was a signiﬁcant increase (pb0.05) in the relative organ weight
and the activities of renal AST, ALT and ALP in the diabetic group of rats
with notable (pb0.05) decline in their body weight and creatinine
clearance rate. However, control rats treated with resveratrol did not
reveal any statistical signiﬁcant on these indices when compared to that
of control rats. Oral treatment with resveratrol as well as glyclazide to
diabetic groups of rats signiﬁcantly (pb0.05) normalized the altered
levels when compared with diabetic group of rats.
3.3. Resveratrol enhances plasma adiponectin and C-peptide levels in
diabetic rats
Fig. 2A and B depicts the effect of resveratrol on the levels of
plasma adiponectin and plasma C-peptide in the control and
experimental groups of rats. Oral treatment with resveratrol to
control group of rats did not show any statistical signiﬁcance on the
levels of plasma adiponectin and C-peptide in comparison with
control group of rats. Conversely, these levels were declined
signiﬁcantly (pb0.05) in diabetic group of rats. However, resveratrol
treatment, as in glyclazide treatment, to diabetic group of rats
signiﬁcantly (pb0.05) improved these levels to near normalcy when
compared with diabetic group of rats.
3.4. Resveratrol normalizes polyol pathway enzymes in diabetic kidney
The activities of renal polyol pathway enzymes such as aldose
reductase, sorbitol dehydrogenase and glyoxalase-I and level of AGEformation are represented in Table 3. The diabetic group of rats
demonstrated a signiﬁcant (pb0.05) escalation on the activities of
renal aldose reductase and sorbitol dehydrogenase and level of AGEs
with a signiﬁcant (pb0.05) decline in the activity of glyoxalase-I in
comparison with control group of rats. Conversely, oral treatment
with resveratrol as well as glyclazide to diabetic group of rats
signiﬁcantly (pb0.05) normalized polyol pathway ﬂux to near control
values than that of diabetic group of rats. However, resveratrol
treatment to control group of rats did not show any statistical
difference in comparison to control group of rats.
3.5. Resveratrol abates proinﬂammatory cytokines in diabetic kidney
The effect of oral treatment of resveratrol on the levels of TNF-α,
IL-1β, IL-6 and NF-κB p65 subunit in renal tissues of control and
experimental groups of rats is demonstrated in Fig. 3A–D. The levels of
TNF-α, IL-1β, IL-6 and NF-κB p65 subunit in control rats administered
with resveratrol did not reveal any statistical difference when
compared with that of control group of rats. Conversely, these
proinﬂammatory cytokine levels were escalated (pb0.05) signiﬁcant-
ly in diabetic group of rats in comparison with control group of rats.
Moreover, oral treatment with resveratrol as well as glyclazide to
diabetic group of rats signiﬁcantly (pb0.05) altered the levels to near
normalcy when compared with diabetic group of rats.
3.6. Resveratrol scavenges superoxide, hydroxyl andNO radical formation in
diabetic kidney
Fig. 4A–C illustrates the effect of resveratrol on the levels of
superoxide anion, hydroxyl radical and NO in the renal tissues of
control and experimental groups of rats. The levels of superoxide
anion, hydroxyl radical and NO in diabetic group of rats were
signiﬁcantly (pb0.05) escalated when compared with control group
Table 2
Effect of resveratrol on the body weight, relative kidney weight, creatinine clearance and the activities of renal AST, ALT and ALP in the control and experimental groups of rats.
Groups Body weight (g) Relative kidney weight Creatinine clearance AST ALT ALP
Control 180.15±2.18 0.95±0.02 2.66±0.33 54.09±2.01 150.78±9.64 0.23±0.02
Control+resveratrol 183.29±3.14 0.97±0.01 2.67±0.52 52.65±2.38 147.11±4.93 0.22±0.01
Diabetic control 138.68±2.34a 1.52±0.05a 1.35±0.05a 107.33±5.74a 293.68±9.22a 0.56±0.05a
Diabetic+resveratrol 165.09±3.08b 1.09±0.02b 2.16±0.17b 69.80±1.98b 176.67±5.51b 0.42±0.02b
Diabetic+glyclazide 169.11±4.03b 1.12±0.02b 2.09±0.28b 75.11±2.61b 183.35±6.13b 0.45±0.01b
Values are given as mean±SEM for groups of six rats in each. One-way ANOVA followed by post hoc test LSD. Values are statistically signiﬁcant at pb0.05.
Units: creatinine clearance, ml/min/100 g body weight; AST and ALT, nmoles of pyruvate/h/mg protein; ALP, μmoles of phenol liberated/min/mg protein.
a Diabetic rats were compared with control rats.
b Diabetic+resveratrol and diabetic+glyclazide treated diabetic rats were compared with diabetic rats.
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to diabetic group of rats demonstrated a marked (pb0.05) decrement
in the levels of superoxide anion, hydroxyl radical and NO. No
considerable statistical variationwas experienced in the control group
of rats treated with resveratrol alone.3.7. Resveratrol restrains the formation of lipid peroxides, hydroperoxides
and protein carbonyl in diabetic kidney
The effect of resveratrol on the levels of lipid peroxides,
hydroperoxides and protein carbonyls in the renal tissues of control
and experimental groups of rats is illustrated in Table 4. No signiﬁcant
statistical deviation was calculated on the levels of renal lipid
peroxides, hydroperoxides and protein carbonyls in control group of
rats treated with resveratrol alone. On the other hand, there was a
signiﬁcant (pb0.05) escalation observed on the levels of lipid
peroxides, hydroperoxides and protein carbonyls in renal tissues of
diabetic group of rats and were decreased (pb0.05) signiﬁcantly toFig. 2. Effect of resveratrol on the plasma levels of (A) adiponectin and (B) C-peptide in
the control and experimental groups of rats. Values are expressed as mean±SEM for
groups of six rats in each. Statistical signiﬁcance was determined by one-way ANOVA
followed by post hoc test LSD. Asterisk (*) indicating a pb0.05versus control rats;
double asterisk (**) indicating a pb0.05 versus diabetic rats.near normalcy by the treatment of resveratrol as well as glyclazide to
diabetic groups of rats.
3.8. Resveratrol enhances the levels of non-enzymatic antioxidants in
diabetic kidney
The levels of renal non-enzymatic antioxidants such as vitamin C,
vitamin E and GSH are exempliﬁed in Table 5. The diabetic group of
rats demonstrated a signiﬁcant (pb0.05) decline on the levels of renal
non-enzymatic antioxidants in comparison with control group of rats.
Conversely, oral treatment with resveratrol as well as glyclazide to
diabetic group of rats signiﬁcantly (pb0.05) improved the levels to
near control values than that of diabetic group of rats. However,
resveratrol treatment to control group of rats did not show any
statistical difference in comparison to control group of rats.
3.9. Resveratrol fosters the activities of enzymatic antioxidants in
diabetic kidney
Table 6 indicates the effect of resveratrol on the activities of renal
enzymatic antioxidants such as SOD, catalase, GPx, GST and GR in the
control and experimental groups of rats. The activities were
signiﬁcantly (pb0.05) diminished in the renal tissues of diabetic
group of rats. Oral treatment of resveratrol, similar to that of
glyclazide, signiﬁcantly (pb0.05) attenuated the altered activities of
these enzymic antioxidants to near normalcy in renal tissues of
diabetic rats. However, no signiﬁcant statistical changes were
observed in rats treated with resveratrol in comparison to that of
control group of rats.
3.10. Resveratrol normalizes the mRNA expression of Nrf2, Keap1, γ-Gcsh
and Gstm3 in diabetic kidney
The effect of resveratrol on themRNA expression ofNrf2, Keap1, γ-
Gcsh and Gstm3 in the kidney tissues of control and experimental
groups of rats is depicted in Fig. 5. The mRNA expression of Nrf2 and
its downregulatory genes such as γ-Gcsh and Gstm3 was signiﬁcantly
(pb0.05) declined with simultaneous elevation of Keap1 gene in the
renal tissues of diabetic group of rats. However, these altered mRNA
expressions were signiﬁcantly (pb0.05) normalized in the diabetic
group of rats by oral administration of resveratrol as well as
glyclazide. On the contrary, resveratrol treatment to control group
of rats did not demonstrate any statistical difference in comparison to
control group of rats.
3.11. Resveratrol normalizes the protein expression of Nrf2, Keap1, γ-GCS,
μ-GST and HO-1 in diabetic kidney
Fig. 6 depicts the effect of resveratrol on the protein expression of
Nrf2, Keap1, γ-GCS, μ-GST and HO-1 in the kidney tissues of control
and experimental groups of rats. The expression of Nrf2 and its
downregulatory proteins such as γ-GCS, μ-GST and HO-1 was
signiﬁcantly (pb0.05) decreased with concomitant elevation in
Table 3
Effect of resveratrol on the renal activities of aldose reductase, sorbitol dehydrogenase and glyoxalase-I and serum level of AGEs in control and experimental groups of rats.
Groups Aldose reductase Sorbitol dehydrogenase Glyoxalase-I Serum AGEs
Control 1.13±0.05 4.62±0.16 288.60±7.14 488.50±23.96
Control+resveratrol 1.19±0.08 4.55±0.15 302.10±5.87 509.20±17.34
Diabetic control 2.76±0.12a 9.54±0.57a 132.50±6.86a 945.50±19.29a
Diabetic+resveratrol 1.69±0.07b 6.56±0.36b 205.30±6.79b 749.80±15.34b
Diabetic+glyclazide 1.75±0.08b 7.36±0.33b 213.85±5.99b 722.60±12.07b
Units: aldose reductase, nmoles/min/mg protein; sorbitol dehydrogenase, units/g protein; glyoxalase-I, nmoles/min/mg protein; serum AGEs, μg/ml.
Values are given as mean±SEM for groups of six rats in each. One-way ANOVA followed by post hoc test LSD. Values are statistically signiﬁcant at pb0.05.
a Diabetic rats were compared with control rats.
b Diabetic+resveratrol and diabetic+glyclazide treated diabetic rats were compared with diabetic rats.
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altered protein expressions were signiﬁcantly (pb0.05) normalized in
the diabetic group of rats by the oral administration of resveratrol as
well as glyclazide. Conversely, resveratrol treatment to control group
of rats did not demonstrate any statistical difference in comparison to
control group of rats.
3.12. Resveratrol protects the histology of diabetic kidney
Fig. 7A–E depicts the photomicrographs of hematoxylin–eosin
staining of renal tissues of control and experimental groups of rats.
Fig. 7A shows the section of renal tissue of control rats demonstrating
normal architecture with normal glomeruli and tubules. Similarly, the
sections of renal tissues of control group of rats treated with
resveratrol also revealed an equivalent architecture (Fig. 7B). Fig. 7C
portrays the section of renal tissues of diabetic group of rats exhibiting
tubular cell necrosis, tubular lumen dilation, foci of denuded
basement membrane, intraluminal casts, swelling or ﬂattening of
proximal tubular cells with brush border loss, diffuse interstitial
edema, interstitial inﬂammatory cell inﬁltrates vacuolization, pykno-
tic nuclei, medullary congestion, hyaline casts, epical blebbing andFig. 3. Effect of resveratrol on the renal levels of (A) TNF-α, (B) IL-1β, (C) IL-6 and (D) NF-
mean±SEM for groups of six rats in each. Statistical signiﬁcance was determined by one-wa
rats; double asterisk (**) indicating a pb0.05 versus diabetic rats.decreased cellularity of the glomeruli. Fig. 7D demonstrates the
section of renal tissues of diabetic group of rats treated with
resveratrol presenting a normal glomerular, renal tubule and
interstitial tissue appearance. Likewise, the renal tissues of diabetic
rats treated with glyclazide show similar pattern of renal histological
architecture (Fig. 7E) and are comparable with control group of rats.
3.13. Resveratrol protects the ultrastructure of diabetic kidney
The ultrastructural changes occurred in kidney of control and
experimental groups of rats are shown in Fig. 8A–E. Fig. 8A represents
the electronmicrograph of kidney of control group of rats showing the
normal glomeruli, renal tubules, podocytes and mesangial cells.
Similar architecture is observed in the electron micrograph of control
group of rats treated with resveratrol (Fig. 8B). The electron
micrograph of kidney of diabetic group of rats (Fig. 8C) revealed the
glomerular ﬁltration barrier, i.e., thickened basement membrane,
decreased number of podocytes, loss of podocytes foot processes,
reduction of mesangial cells around the ﬁltration barrier, capillary
with fenestrated endothelial layer, disruption of basal infoldings of
proximal and distal convoluted tubules, decreased number ofκB p65 subunit in the control and experimental groups of rats. Values are expressed as
y ANOVA followed by post hoc test LSD. Asterisk (*) indicating a pb0.05 versus control
Fig. 4. Effect of resveratrol on the renal levels of (A) superoxide anion, (B) hydroxyl
radical and (C) NO in control and experimental groups of rats. Values are expressed as
mean±SEM for groups of six rats in each. Statistical signiﬁcance was determined by
one-way ANOVA followed by post hoc test LSD. Asterisk (*) indicating a pb0.05versus
control rats; double asterisk (**) indicating a pb0.05 versus diabetic rats.
Table 4
Effect of resveratrol on the levels of lipid peroxides, hydroperoxides and protein
carbonyls in the kidney tissues of control and experimental groups of rats.
Groups Lipid peroxides Hydroperoxides Protein carbonyls
Control 1.18±0.10 54.24±1.94 4.49±0.19
Control+resveratrol 1.27±0.07 54.59±1.78 4.45±0.17
Diabetic control 3.83±0.19a 82.81±2.30a 15.41±0.86a
Diabetic+resveratrol 1.99±0.07b 64.50±2.88b 8.65±0.40b
Diabetic+glyclazide 2.02±0.09b 62.29±1.50b 7.58±0.36b
Values are given as mean±SEM for groups of six rats in each. One-way ANOVA
followed by post hoc test LSD. Values are statistically signiﬁcant at pb0.05.
Units: lipid peroxides, mmoles of TBARS/100 g tissues; hydroperoxides, mmoles/100 g
tissues; protein carbonyls, nmoles/mg protein.
a Diabetic rats were compared with control rats.
b Diabetic+resveratrol and diabetic+glyclazide treated diabetic rats were com-
pared with diabetic rats.
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electron micrograph (Fig. 8D) apparently shows the renal tissue
protective nature of resveratrol in diabetic group of rats by virtue of an
apparent appearance of normal architecture. Likewise, the electron
micrograph of kidney of diabetic group of rats treated with glyclazide
showing similar pattern of renal tissue protection (Fig. 8E) is
comparable with control group of rats (Fig. 8A).
4. Discussion
The present investigation demonstrates the renoprotective potential
of resveratrol against hyperglycemia-mediated oxidative stress in
streptozotocin–nicotinamide-induced diabetic nephropathy. Diabetic
nephropathy is one of the major microvascular complications and is a
leading cause of end-stage renal disease. The pathogenesis of diabetic
nephropathy is multifactorial in which chronic hyperglycemia plays a
crucial role [43]. During diabetic milieu, supraphysiological glucose is
involved in the formation of AGEs and the mitochondrial production of
free radicals and consequently, to cell death and renal dysfunction. Thus,
oxidative stress plays a decisive role in the development of diabetic
nephropathy, which is characterized by thickening of glomerular
basement membranes, expansion of mesangial cells, glomerular
hypertrophy and loss of podocytes, expansion of tubular basement
membranes, tubular atrophy, interstitial ﬁbrosis and arteriosclerosis
[44].
The pathophysiological alterations and deteriorated renal func-
tions established by chronic hyperglycemia-mediated oxidative stress
in the experimental rats are closely similar to that of human diabetic
nephropathy. Further, streptozotocin–nicotinamide-induced experi-
mental diabetes is exempliﬁed by moderate and stable hyperglyce-
mia, glucose intolerance and signiﬁcantly altered glucose-stimulated
insulin secretion that contributes number of features comparable to
human diabetes [21]. The elevated blood glucose, increased kidney
weight, altered intraperitoneal insulin tolerance, increased activities
of renal AST, ALT and ALP and diminished creatinine clearance in the
diabetic group of rats indicate the development of renal hypertrophy,
glomerular injury and renal dysfunction. However, oral treatment
with resveratrol to diabetic group of rats normalized these altered
levels into near normalcy, suggesting that resveratrol effectively
ameliorates diabetic renal injury in addition with attenuating
oxidative stress as well as limiting the activation of polyol pathway.
Adiponectin, an adipose-speciﬁc protein, is an insulin-sensitizing,
anti-inﬂammatory and vasculo-protective cytokine and has been
shown to improve glucose tolerance and insulin resistance in
experimental animals [45] and humans [46]. The elevated level of
plasma adiponectin is directly interrelated with reduced likelihood of
moderate diabetic renal dysfunction [47]. The increased levels of
proinﬂammatory cytokines such as TNF-α and IL-6 in experimental
diabetes may be responsible for the decline in level of plasma
adiponectin [48]. The results of the present investigation revealed that
oral treatment with resveratrol may improve the renal function by
escalating the plasma adiponectin concentration in the diabetic rats.
However, the mechanisms by which resveratrol treatment fosters the
level of circulating adiponectin is unknown, but it is possible that
inhibition of TNF-α increases the secretion of both plasminogen
activator inhibitor-1 and IL-6 and recovers the insulin resistance,
resulting in an elevation of adiponectin [49]. Thus, resveratrol might
enhance plasma adiponectin level through its anti-inﬂammatory
mechanisms.
C-peptide is a cleavage product of insulin biosynthesis and is
subsequently released along with insulin in equimolar quantities to
the circulation. It is considered to be a reliable marker of residual β-
cell function. The prime task of C-peptide is to facilitate proper folding
of proinsulin by assisting disulﬁde bonds formation within A- and B-
chains [50]. It possesses insulin-mimetic property, thereby activates
insulin receptors and increases the rate of glycogenesis and
Table 5
Effect of resveratrol on the levels of kidney non-enzymatic antioxidants such as vitamin C, vitamin E and GSH in control and experimental groups of rats.
Groups Vitamin C (μg/mg protein) Vitamin E (μg/mg protein) GSH (mg/100 g wet tissue)
Control 1.34±0.05 1.03±0.04 33.52±1.53
Control+resveratrol 1.42±0.03 1.01±0.03 31.84±1.21
Diabetic control 0.43±0.02a 0.47±0.02a 20.57±0.88a
Diabetic+resveratrol 0.94±0.03b 0.93±0.02b 29.22±1.02b
Diabetic+glyclazide 0.97±0.02b 0.85±0.03b 29.28±0.94b
Values are given as mean±SEM for groups of six rats in each. One-way ANOVA followed by post hoc test LSD. Values are statistically signiﬁcant at pb0.05.
a Diabetic rats were compared with control rats.
b Diabetic+resveratrol and diabetic+glyclazide treated diabetic rats were compared with diabetic rats.
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reported to alleviate incipient diabetic nephropathy by reducing
glomerular hyperﬁltration, improving functional reserve, reducing
urinary albumin excretion and preventing glomerular and renal
hypertrophy in diabetic rats [51]. The oral administration of
resveratrol to diabetic group of rats elevated the C-peptide level
through activating remnant pancreatic β-cells.
It is well-known that diabetes is associated with chronic
hyperglycemia and one of the foremost consequences of hyperglyce-
mia is an increased rate of oxidative phosphorylation as well as the
activation of the polyol pathway. Aldose reductase, the ﬁrst and rate-
limiting enzyme in polyol pathway, catalyzes the NADPH dependent
reduction of glucose to sorbitol. Sorbitol is consequently converted to
fructose by sorbitol dehydrogenase with NAD+ as cofactor. The
fructose and its metabolites are involved in the non-enzymatic
glycation of cellular proteins and lipids in the kidney and other
organs, which aggravate AGE formation and glycative injury.
Intracellular accumulation of sorbitol impedes myo-inositol uptake
and its metabolism and declines Na+-K+-ATPase activity [52,53],
leading to dysfunction in renal tubular reabsorption. The oxidation of
sorbitol by NAD+ elevates cytosolic NADH:NAD+ ratio, thereby
hindering the glyceraldehyde-3-phosphate dehydrogenase activity
and increasing triose phosphate level. Enhanced triose phosphate
concentrations could augment the formation of both methylglyoxal, a
precursor of AGEs, and diacylglycerol, thus activating protein kinase C
signaling [54]. Hence, the augmented polyol pathway ﬂux has been
suggested to induce overexpression of various cytokines and signaling
proteins that are responsible for the thickening of the glomerular
basement membrane and progressive accumulation of extracellular
matrix components in themesangium. Thus, both oxidative stress and
increased aldose reductase and sorbitol dehydrogenase activities are
implicated in the pathogenesis of diabetic nephropathy [55].
Glyoxalase-I is a GSH-dependent detoxifying enzyme involved in
metabolism of methylglyoxal, thereby suppressing the available
precursors for AGE formation under hyperglycemic conditions.
Because the elevated production of methylglyoxal, a precursor for
AGE formation, has been directly associated to the development of
diabetic nephropathy [56]. Thus glyoxalase-I is involved in the
metabolism of these physiological reactive carbonyl compounds in
tissues especially in the kidney; therefore, glycative stress could beTable 6




Diabetic control 9.82±0.67a 22.41±1.36a
Diabetic+resveratrol 14.25±0.51b 32.85±1.16b
Diabetic+glyclazide 13.87±0.48b 33.01±1.01b
Values are given as mean±SEM for groups of six rats in each. One-way ANOVA followed b
Activity is expressed as: 50% of inhibition of epinephrine autoxidation/min for SOD; μmoles
oxidized/min/mg protein for GPx; units/min/mg protein for GST; μmoles of DTNB-GSH con
a Diabetic rats were compared with control rats.
b Diabetic+resveratrol and diabetic+glyclazide treated diabetic rats were compared wattenuated. Various studies have signiﬁed that elevated activity or
expression of glyoxalase-I could decline AGE formation via lowering
their precursors such as methylglyoxal [57,58]. The results of the
present study indicated that oral administration of resveratrol
improved the glyoxalase-I activity, which further efﬁciently metab-
olized methylglyoxal. Thus, these enzymes have been considered as
therapeutic targets for improving glycation associated diabetic
complications including diabetic nephropathy. Moreover, the present
investigation reveals that oral administration of resveratrol moder-
ated renal activity of aldose reductase and sorbitol dehydrogenase and
improved the activity of glyoxalase-I, which consequently led to
declined formation of sorbitol and fructose in kidney. This observation
indicated that resveratrol could assuage diabetic renal glycative
damage via restraining polyol pathway and declining AGE formation.
Inﬂammation and proinﬂammatory cytokines have been sug-
gested to play a signiﬁcant role in the development and progression of
diabetic nephropathy. TNF-α , IL-1β and IL-6 are essentially produced
by intrinsic renal cells together with dendritic, endothelial, glomer-
ular, mesangial and renal tubular cells, because the expression and
synthesis of these cytokines are not only restricted to hematopoietic
cells. Therefore, these cytokines, acting in a paracrine or autocrine
manner, may induce a variety of effects on different renal structures.
The signiﬁcant elevation in the wet weight of kidney is an accurate
index of renal hypertrophy and one of the earliest renal changes
during diabetes and directly related to renal TNF-α, IL-1β and IL-6
expressions [59].
TNF-α is cytotoxic to glomerular, mesangial and epithelial cells
and competent to induce direct renal injury through the generation of
reactive free radicals in various cells, including mesangial cells. IL-1β
is also involved in the development of abnormalities in intraglomer-
ular hemodynamics related to prostaglandin synthesis by mesangial
cells [60]. IL-1β together with TNF-α may provoke the expression of
iNOS in glomerular mesangial cells, which results in the production of
large amounts of NO and causes an elevation of cellular cGMP
concentrations. Moreover, streptozotocin–nicotinamide-induced dia-
betic nephropathy is also associated with nitrosative stress; strepto-
zotocin itself is a NO donor and liberates this reactive species during
its intracellular metabolism. The excessive formation of NO and cGMP
bymesangial cells not only alters the contractile responses of the cells







y post hoc test LSD. Values are statistically signiﬁcant at pb0.05.
of hydrogen peroxide decomposed/min/mg protein for catalase; μmoles of glutathione
jugate formed/min/mg protein for GR.
ith diabetic rats.
Fig. 5. Effect of resveratrol on the renal mRNA expression levels of Nrf2, Keap1, γ-Gcsh and Gstm3 in control and experimental groups of rats. Values are expressed as mean±SEM for
groups of six rats in each. Statistical signiﬁcance was determined by one-way ANOVA followed by post hoc test LSD. Asterisk (*) indicating a pb0.05 versus control rats; double
asterisk (**) indicating a pb0.05 versus diabetic rats.
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[61,62].
IL-6 accelerates mesangial cell proliferation, enhances ﬁbronectin
expression, affects extracellular matrix dynamics at both mesangial
and podocyte levels and increases endothelial permeability. Recent
investigations on diabetics established a signiﬁcant association
between IL-6 and glomerular basement membrane thickening, a
crucial lesion of diabetic nephropathy and a strong predictor of renal
progression [63]. During hyperglycemia, increased activation of NF-κB
is closely associated with regulation of mesangial cell proliferation
that has been suggested to be a key step in the pathogenesis of
diabetic nephropathy. Then the activated NF-κB is translocated into
the nucleus and results in the transcriptional expression of genes
associated with cellular growth properties. This may contribute to the
accumulation of renal extracellular matrix and tubulointerstitial
ﬁbrosis, resulting in kidney damage [64]. The present study indicates
that the oral administration of resveratrol to diabetic rats signiﬁcantly
attenuates the elevated levels of renal TNF-α, IL-1β and IL-6 in
experimental diabetic rats to near normalcy, thereby moderating the
consequence of inﬂammation-mediated oxidative tissue damage.
There is coercing evidence that surplus level of superoxide generated
by diabetic hyperglycemia plays a vital role in diabetic kidney damage.
The total amassing of superoxide anion is determined by a balancebetween superoxide anion production and antioxidant competence.
Elevated glucose ﬂux enhances the generation of superoxide anion by
mitochondrial electron-transport chain and the overproduced superox-
ide anion augments the major pathways such as protein kinase C, AGE
products and hexosamine pathways [65]. Various pathogenic pathways
of diabetes such as increased NADPH oxidase activity, uncoupled
endothelial nitric oxide synthase and enhanced signaling of AGEs,
angiotensin II and oxidized-LDL receptors are also responsible for
inexorable generation of superoxide anion. Further, the elevated
generation of superoxide anion leads to the formation of secondary
reactive free radicals including peroxynitrite and hydroxyl radicals,
leading to damage of DNA, proteins and lipids and triggering renal cell
injury [66]. The instantaneous overproduction of NO and superoxide
facilitates the production of a cytotoxic peroxynitrite anion that in turn
oxidizes sulfydryl groups in proteins, instigates lipid peroxidation and
nitrates amino acids such as tyrosine, which affects several signal
transduction pathways [67]. Thus free radicals are implicated in the cell
destruction and progression of kidney tubular damage and the results of
the present investigation speculate that these free radicals could be
signiﬁcant in the pathogenesis of renal tissue damage at the later stages
of experimental diabetes mellitus. However, oral treatment of resver-
atrol efﬁciently scavenges these free radicals, thereby protecting the
kidney tissue from free radical-mediated damage.
Fig. 6. Effect of resveratrol on the renal protein expression levels of Nrf2, Keap1, γ-GCS,
μ-GST and HO-1 in control and experimental groups of rats. Values are expressed as
mean±SEM for groups of six rats in each. Statistical signiﬁcance was determined by
one-way ANOVA followed by post hoc test LSD. Asterisk (*) indicating a pb0.05 versus
control rats; double asterisk (**) indicating a pb0.05 versus diabetic rats.
Fig. 7. Photomicrographs of hematoxylin–eosin staining of renal tissues of control and
experimental groups of rats. Diabetes was induced by single intraperitoneal injection of
streptozotocin (50 mg/kg bodyweight), 15 min after the intraperitoneal administration of
nicotinamide (110 mg/kg body weight). Resveratrol (5 mg/kg body weight) was orally
administered daily for 30 days, as described under Materials and methods section. At the
endof experimental period, the ratswerekilled and the renal tissueswere sectioned for the
histological studies. Histological photograph of (A) control, (B) control+resveratrol,
(C) diabetic, (D) diabetic+resveratrol and (E) diabetic+glyclazide treated rats’ renal
tissue sectionswere shown at 100×magniﬁcation. Distal tubules (DT), glomerulus (G) and
proximal tubules (PT). Scale bar, 0.1 mm.
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secondary products of oxidative stress and are unleashed as a result of
the toxic effect of reactive oxygen species produced during lipid
peroxidation in diabetes. Lipid peroxidation may also play a crucial
role in diabetic glomerulosclerosis. The initial hyperﬁltering phase of
diabetic kidney disease, heralded by the presence of microalbumi-
nuria, is followed by gross proteinuria, progressive diminution in
glomerular ﬁltration rate and excessive amassing of extracellular
matrix proteins in the glomerular capillaries and mesangium. The
latter process leads the way to eventual glomerulosclerosis and renal
failure [68]. The results of the present study are also in line with the
previous studies, in which resveratrol administration to diabetic
group of rats notably declined the levels of renal lipid peroxides,
hydroperoxides and protein carbonyls [69]. This normalization may
be accomplished by the antioxidant and free-radical quenching nature
of resveratrol, because resveratrol is reported to protect the cells from
peroxidative stress and lipid peroxidation as well as oxidized
lipoprotein-mediated cell death [70,71].
Chronic hyperglycemia often associated with a notable decline in
the level of intracellular antioxidants and elevation in the formation of
pro-oxidants such as reactive free radicals and electrophilic sub-
stances that eventually results in renal dysfunction and deterioration.There are a number of enzymatic and non-enzymatic sources of
reactive free radicals in the diabetic kidney, such as autoxidation of
glucose, transition metal-catalyzed Fenton reactions, AGEs, polyol
pathway ﬂux, mitochondrial respiratory chain deﬁciencies, xanthine
oxidase activity, peroxidases, nitric oxide synthase and NAD(P)H
oxidase [44]. Such glucotoxicity possibly related to the vulnerability of
renal tissues to oxidative stress, because both the functional activities
and expression levels of antioxidant enzymes such as SOD, catalase,
GPx, GST and GR, are forced to overcome the susceptibility rates. SOD,
a chief antioxidant enzyme for the removal of superoxide anion,
dismutates superoxide into hydrogen peroxide andmolecular oxygen.
The hydrogen peroxide is further detoxiﬁed to water by catalase or
GPx. In addition, GPx is involved in diminution of highly cytotoxic
products such as lipid peroxides and other organic hydroperoxides.
GSH is an essential cosubstrate for the activity of GPx that oxidizes the
GSH into oxidized glutathione. Oxidized glutathione is recycled back
to glutathione by GR, through an NADPH consuming process [72].
Hence, the activities of these key enzymatic antioxidants are
diminished during oxidative stress. However, oral treatment of
resveratrol signiﬁcantly improved the activities of enzymatic antiox-
idants. In this context, various studies have reported the diminished
activities of these antioxidant enzymes in the diabetic kidney and
several compounds with antioxidant activity have been shown to
Fig. 8. Transmission electronmicrographs of renal tissues of control and experimental groups of rats. Diabetes was induced by single intraperitoneal injection of streptozotocin (50 mg/kg
body weight), 15 min after the intraperitoneal administration of nicotinamide (110 mg/kg body weight). Resveratrol (5 mg/kg body weight) was orally administered daily for 30 days, as
described under Materials and methods section. At the end of experimental period, the rats were sacriﬁced and the renal tissues were sectioned for the transmission electron microscopic
studies. Transmission electron micrographs of (A) control, (B) control+resveratrol, (C) diabetic, (D) diabetic+resveratrol and (E) diabetic+glyclazide treated rats’ renal tissue sections
were shown at ×2000, ×1500, ×15,000, ×10,000, and×4500magniﬁcation, respectively. Basementmembrane (BM), capillary loop (CL), endothelial fenestrations (EF),mesangial cell (MC),
microtubules (MT), nucleus (N), podocytes (P), red blood cells (R), urinary space (US). Scale bar, 1 μm.
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[18,73,74].
The inexorable generation of reactive free radicals and lipid
peroxides during diabetes-mediated oxidative stress could be
correlated to decline in the level of non-enzymatic antioxidants
such as GSH, vitamin C and vitamin E. GSH improves the scavenging
capacity against free radicals induced oxidative stress in diabetic rats.
Polyphenols are reported to enhance the activity of γ-glutamylcys-
teine synthetase and demonstrated simultaneous escalation in the
intracellular glutathione level [75]. In addition to GSH, vitamin C and
vitamin E are interrelated by recycling processes, because recycling of
tocopheroxyl radicals to tocopherol is accomplished by reaction with
ascorbic acid and dehydroascorbic acid is also produced in reaction
with GSH. Studies have revealed the existence of a liable glutathione
dependent factor, which recycles the tocopheroxyl radicals to
tocopherol. If recycling of tocopheroxyl radicals to tocopherol is a
key mechanism for preservation of tissue tocopherol level, ascorbic
acid insufﬁciency is predictable to result in exhaustion of tissue
tocopherol. In the present study, the levels of GSH, vitamin C and
vitamin E are declined in the diabetic kidney portending the recycling
of tocopheroxyl radicals to tocopherol may have been impeded that
results in elevated lipid peroxidation [76]. However, the oral
administration of resveratrol to diabetic rats notably elevated the
renal levels of GSH, vitamin C and vitamin E. It is evidenced that
polyphenols like resveratrol, owing to their intermediate redox
potential and physiochemical characteristics, can probably act an
interface between vitamin C and vitamin E [77].Nrf2, a member of the cap-N-collar family, is the key transcription
factor that regulates antioxidant response element-mediated expres-
sion of detoxifying antioxidant enzymes [78]. Under basal conditions,
Nrf2 is sequestered in the cytoplasm by an actin binding repressor
protein-Keap1. Upon exposure of cells to oxidative stress or
electrophilic compounds with the capacity to oxidize or covalently
transform thiol groups, Nrf2 easily dissociates from its repressor
protein, translocates into the nucleus, binds to antioxidant response
elements and transactivates the genes of detoxifying and antioxidant
enzymes such as γ-GCL, μ-GST and HO-1 [79]. During hyperglycemia-
mediated oxidative stress, the expression of Nrf2 and its down-
regulatory enzymes like γ-GCL, μ-GST and HO-1 were signiﬁcantly
decreased in the renal tissues of diabetic rats. However, resveratrol
treatment signiﬁcantly modulates the expression of Nrf2 in hyper-
glycemia-mediated oxidative stress by upregulation of γ-GCL, μ-GST
and HO-1.
The renal tissue defensive nature of resveratrol in control and
experimental groups of rats was ascertained by histological as well as
ultrastructural studies, respectively. The diabetogenic potential of
streptozotocin is accountable for a progressive development of the
renal tissues lesions. The major morphological abnormalities ob-
served in the diabetic kidney was tubular cell swelling, cellular
vacuolization, pyknotic nuclei, medullary congestion, severe lesions
and necrosis in a large number of proximal tubular cells, hemorrhagic
and hyaline cast deposits, apical blebbing, glomerulus hypertrophy,
expanded and congested glomerular capillaries, lysis in tubular
epithelial cells and irregular tubular lumens, with reference to control
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the histological observations showing the dysfunction and deteriora-
tion of the diabetic kidney ultrastructure. The electron microscopy of
diabetic kidney has revealed disruption of the podocytes foot
processes, with disruption of the basal infoldings and loss of
mitochondria between the folds of proximal convoluted tubules.
Mesangiolysis, subendothelial edema as well as focal podocyte
degeneration and detachment were also observed along with
enlargement of the inner layer of glomerular basement membrane
and disruption of ﬁbrils in the middle layer of glomerular basement
membrane and in mesangium of the kidney tissues of diabetic rats
[81,82]. However, administration of resveratrol to diabetic rats
ameliorated all of those ultrastructural alterations in the kidney
tissues conﬁrming its protective nature during diabetes. There are no
such studies available on the protective nature of resveratrol on the
kidney tissue ultrastructure during experimental diabetes. Hence, this
investigation should be considered an innovative assessment for the
renal tissue protective nature of resveratrol in rats insulted by
streptozotocin.
Thus, the present study divulges the renoprotective nature of
resveratrol in streptozotocin–nicotinamide-induced diabetic rats and
provides evidence that the protective effects are, possibly, due to the
decline in oxidant and proinﬂammatory cytokine production by the
renal tissues. Moreover, resveratrol treatment to streptozotocin–
nicotinamide-induced diabetic rats exhibited a signiﬁcant ameliorative
potential probably by attenuating the hyperglycemia-mediated oxida-
tive stress, thereby alleviating the ultrastructural alterations such as
tubulonecrosis, glomerulosclerosis, glomerular basement membrane
thickening and changes in the proximal and convoluted tubules. Further
detailed studies are in progress to explicate the precise mechanism by
which resveratrol reduces its renoprotective potentials.Acknowledgements
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